拉莫三嗪(Lamotrigine) - 药物靶点：Sodium channels_在研适应症：失神发作，全身性癫痫，躁郁症1型_专利_临床

概要

基本信息

简介拉莫三嗪是一种抗惊厥药物，于1994年12月27日首次被美国食品和药品管理局批准上市。由制药公司葛兰素史克开发的，主要用于治疗Lennox Gastaut综合征、癫痫和双相情感障碍等疾病。拉莫三嗪的作用机制是通过阻断大脑中的钠通道，以稳定神经元的电活动，减轻癫痫发作的严重程度和频率。此外，拉莫三嗪还被用于治疗双相情感障碍的抑郁症状。该药物已被证明对减少癫痫发作的频率和改善患者生活质量具有显著疗效。

药物类型

小分子化药

别名

3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine、Lamotrigine (JAN/USP/INN)、430-C-78

+ [14]

靶点

Sodium channels

作用方式

阻滞剂

作用机制

钠通道阻滞剂

治疗领域

神经系统疾病遗传病与畸形其他疾病+ [2]

在研适应症

失神发作全身性癫痫躁郁症1型+ [6]

非在研适应症

暴食症抑郁症难治性抑郁症+ [9]

原研机构

GSK Plc

在研机构

GlaxoSmithKline KK上海奥科远制药有限公司

GlaxoSmithKline Export Ltd.

+ [4]

非在研机构

北京科信必成医药科技发展有限公司

葛兰素史克（中国）投资有限公司GlaxoSmithKline Pharmaceuticals SA

+ [3]

权益机构

Neuraxpharm Polska Sp zoo

Eton Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Ltd.

+ [3]

最高研发阶段批准上市

首次获批日期

(1990-01-01),

躁郁症

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C9H7Cl2N5

InChIKeyPYZRQGJRPPTADH-UHFFFAOYSA-N

CAS号84057-84-1

关联

235

项与拉莫三嗪相关的临床试验

NCT07140913

/ Recruiting临床3期

A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

开始日期2025-10-08

申办/合作机构

Bristol Myers Squibb Co.

NCT06929273

/ Recruiting临床3期

A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I)
The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

开始日期2025-07-18

申办/合作机构

Bristol Myers Squibb Co.

CTR20252057

/ CompletedN/A

拉莫三嗪分散片的生物等效性试验（餐后用药试验）

主要试验目的：在健康受试者体内，在餐后条件下，以The Wellcome Foundation Limited持有的拉莫三嗪分散片（规格：50 mg，商品名：利必通®）为参比制剂，研究河北龙海药业有限公司研制的拉莫三嗪分散片（规格：50 mg；受试制剂）的药代动力学，评价受试制剂与参比制剂是否具有生物等效性。次要试验目的：观察健康受试者餐后口服受试制剂、参比制剂的安全性。

开始日期2025-06-04

申办/合作机构

河北龙海药业有限公司

100 项与拉莫三嗪相关的临床结果

登录后查看更多信息

100 项与拉莫三嗪相关的转化医学

登录后查看更多信息

100 项与拉莫三嗪相关的专利（医药）

登录后查看更多信息

9,363

项与拉莫三嗪相关的文献（医药）

2026-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Design, synthesis, and computational evaluation of ester prodrugs of isoguvacine as potential antiseizure medications

Article

作者: Maharani, Rani ; Sarian, Murni Nazira ; Feroz, Shevin Rizal ; Bakar, Khairul Azreena ; Ng, Yan Hong ; Supratman, Unang ; Lam, Su Datt ; Latip, Jalifah ; Muhajir, Muhamad Imam

Epilepsy, a neurological disorder affecting millions worldwide, has driven the development of various antiseizure medications (ASMs). Isoguvacine (IGV), a potent and selective agonist of the GABA_A receptor (GABA_AR), has shown potential in the treatment of epilepsy and other neurological disorders. However, its low blood-brain barrier permeability impairs its ability to act effectively within the central nervous system. To address this limitation, two novel ester derivatives of IGV, E7 and E14, were synthesized via Steglich esterification and evaluated through an integrated computational framework comprising density functional theory (DFT) calculations, molecular docking, molecular dynamics (MD) simulations, and in silico ADMET predictions. DFT analysis revealed that esterification significantly modified the electronic properties of IGV, with E14 exhibiting the highest polarizability (225.895 Å³) and smallest energy gap (-0.155 eV), indicative of enhanced reactivity. Molecular docking demonstrated that GABA (-8.46 kcal/mol) and IGV (-8.35 kcal/mol) exhibit similar binding affinity and complex stability with GABA_AR, supporting the reliability of our computational approach. MD simulations further confirmed the stability of these complexes, where lower RMSD, RMSF, and Rg values indicated that binding of GABA and IGV did not induce significant conformational changes in the overall receptor structure. Moreover, the derivatives were projected to exhibit optimal intestinal absorption (>90%), oral bioavailability, as well as favorable safety profiles with minimal interaction risks and non-carcinogenic properties. Collectively, these in silico findings highlight the potential of ester prodrug design to overcome the central pharmacokinetic limitations of IGV, with E14 emerging as the most promising ASM candidate for further experimental development in epilepsy therapy. Beyond identifying therapeutic advantages of E14, this study also underscores the broader value of integrated computational approaches as powerful and predictive tools in early-stage drug discovery for neurological disorders.

2025-12-31·Journal of Maternal-Fetal & Neonatal Medicine

A 10-year review of periconceptual folic acid supplementation in women with epilepsy taking antiseizure medications

Article

作者: O’Higgins, Amy ; McIntosh, Trudi ; Turner, Ciara ; Gaffney, Damon ; Hogan, Jennifer ; Germaine, Mark

BACKGROUND:

Epidemiological studies have reported that women with epilepsy who are taking antiseizure medications have an increased risk of Neural Tube Defects. Periconceptual folic acid supplementation potentially prevents two-thirds of cases. International guidelines recommend that women at increased risk of a pregnancy complicated by a Neural Tube Defect who could become pregnant should start high-dose (5 mg daily) oral folic acid at least three months before conceiving. The purpose of the study was to examine supplementation in women taking antiseizure medications who delivered a baby weighing >499 g during the ten years 2013-2022 in a large maternity hospital.

METHODS:

The hospital's computerized database contains standardized maternal clinical and sociodemographic details which were entered at the first antenatal visit in the obstetric records. The data on all women with epilepsy taking antiseizure medications was anonymized before coding.

RESULTS:

In the ten years, 75,869 women delivered a baby weighing >499 g. Of the deliveries, 632 (0.83%) were to women with epilepsy. Of these, 250 (0.33%) were taking antiseizure medications when they presented for antenatal care. The most frequently prescribed medications were lamotrigine n = 98 (33.8%) and levetiracetam n = 89 (30.7%). Monotherapy was prescribed in 211 (84.4%) women and polytherapy in 39 (15.6%). Three (1.2%) women took no folic acid before or after conception and 59 (23.6%) only took it after conception. Of the 188 (75.2%) who took folic acid before conception, 164 (65.6%) took high-dose 5 mg and 24 (9.6%) took low-dose 0.4 mg. No maternal characteristics were associated with taking high-dose folic acid before conception. Compliance with the national guidelines in the 16 women taking valproate was 30.8% compared with 76.0% for the other 234 women taking medications (p < 0.03). Compliance in the 211 women receiving monotherapy was 72.5% compared with 25.6% in the 39 women receiving polytherapy (p < 0.03).

CONCLUSIONS:

Two-thirds of women taking antiseizure medications complied with national guidelines on high-dose periconceptual folic acid supplementation. A particular concern is the suboptimal compliance in women prescribed valproate and polytherapy, which are two cohorts at higher risk of a neural tube defect. These findings need to be communicated to women with epilepsy in their reproductive years and their doctors.

KEY POINTS:

Of 75,869 women delivered over 10 years, 250 (0.33%) were on medications for epilepsy at presentation34.4% of women taking medications did not start high dose folic acid before conception23.6% of women did not start folic acid until after conceptionCompliance with recommendations was lowest in women prescribed valproate or polytherapyNo maternal characteristics were identified which were associated with suboptimal compliance.

2025-12-31·DRUG DELIVERY

Development, in vitro and ex vivo characterization of lamotrigine-loaded bovine serum albumin nanoparticles using QbD approach

Article

作者: Kiricsi, Ágnes ; Zupkó, István ; Szalenkó-Tőkés, Ágnes ; Csóka, Ildikó ; Rovó, László ; Schelz, Zsuzsanna ; Salamah, Maryana ; Balogh, György Tibor ; Katona, Gábor ; Sipos, Bence

The present study aimed to prepare and optimize lamotrigine-loaded bovine serum albumin nanoparticles (LAM-NP) using the Quality by Design (QbD) approach and to investigate both the in vitro and ex vivo effects of different cross-linking agents glutaraldehyde (GLUT), glucose (GLUC) and 1-(3-dimethylaminutesopropyl)-3-ethylcarbodiimide hydrochloride (EDC) on intranasal applicability. Cross-linked LAM-NP from EDC (NP-EDC-1) showed the lowest Z-average value (163.7 ± 1.9 nm) and drug encapsulation efficacy (EE%) of 97.31 ± 0.17%. The drug release of GLUC cross-linked LAM-NP (NP-GLUC-9), glutaraldehyde cross-linked LAM-NP (NP-GLUT-2), and NP-EDC-1 at blood circulation conditions was higher than the initial LAM. The results of the blood-brain barrier parallel artificial membrane permeability assay (BBB-PAMPA) showed an increase in the permeability of LAM through the BBB with NP-GLUC-9 and an increase in flux with all selected formulations. The ex vivo study showed that LAM diffusion from the selected formulations through the human nasal mucosa was higher than in case of initial LAM. The cytotoxicity study indicated that BSA-NP reduced LAM toxicity, and GLUC 9 mM and EDC 1 mg could be alternative cross-linking agents to avoid GLUT 2% v/v toxicity. Furthermore, permeability through Caco-2 cells showed that nasal epithelial transport/absorption of LAM was improved by using BSA-NPs. The use of BSA-NP may be a promising approach to enhance the solubility, permeability through BBB and decrease the frequency of dosing and adverse effects of LAM.

129

项与拉莫三嗪相关的新闻（医药）

2025-09-17

·EINPresswire

OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® Oral Suspension

The First and Only Lamotrigine Oral Suspension in the U.S. LISLE, IL, UNITED STATES, September 17, 2025 / EINPresswire.com / -- OWP Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved SUBVENITE ® Oral Suspension, the first and only lamotrigine oral suspension in the United States. This innovative formulation will offer treatment options for patients and healthcare providers by offering a flexible, patient-friendly alternative to tablets. Lamotrigine is widely prescribed, but until now only solid oral dosage forms have been available. SUBVENITE ® Oral Suspension is designed for patients who have difficulty swallowing tablets, those who require individualized dosing, or prefer liquid medication formulations. “The FDA approval of SUBVENITE ® Oral Suspension — the first and only lamotrigine oral suspension — represents a significant advancement in patient care,” said Scott Boyer, Founder and President, OWP Pharmaceuticals. “We are proud to bring this much needed treatment option to patients and clinicians, with availability anticipated later in 2025.” Key Features and Benefits of SUBVENITE ® Oral Suspension: - First and only FDA-approved lamotrigine oral suspension in the U.S. - Improved accessibility: Suitable for patients with swallowing challenges, those requiring individualized dosing, or those who prefer liquid medication formulations. - Precision dosing: Liquid formulation allows for dose titration and flexibility. - Therapeutic reliability: Developed to deliver the expected safety and efficacy profile as lamotrigine tablets (1). Availability SUBVENITE ® Oral Suspension has been FDA-approved and is expected to be available in the United States later in 2025 through leading distribution channels. Full prescribing information is available at www.owppharma.com . SUBVENITE is indicated for (2): Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures • primary generalized tonic-clonic (PGTC) seizures • generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients aged 16 years and older: •Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. Bipolar disorder: •Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. About OWP Pharmaceuticals OWP Pharmaceuticals is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations. Based in Chicago, OWP is committed to advancing therapies in neurology and psychiatry, with a mission to bring meaningful innovations to patients. Through its partnership with the ROW Foundation, OWP also supports global initiatives to improve epilepsy care and education in underserved communities worldwide. Media Contact: info@owppharma.com References: 1. DOF: Data on File. OWP Pharmaceuticals, Inc. 2. SUBVENITE ® Oral Suspension [package insert]. Lisle, IL: OWP Pharmaceuticals, Inc.; 2025. info@owppharma.com OWP Pharmaceuticals info@owppharma.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

2025-09-17

·FiercePharma

SK's blockbuster hopeful Xcopri reduces seizures in phase 3 trial, teeing up FDA expansion bid

SK Biopharmaceutical hopes to cross the $1 billion sales marker for Xcopri by 2029. SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of building a blockbuster with an expansion into another seizures subtype.The South Korean pharma won FDA approval for Xcopri in 2019 as a treatment for partial-onset seizures, also known as focal seizures, in adults. Since then, with rapid global growth, SK has outlined blockbuster ambitions for the drug by 2029. Now, with a positive phase 3 trial, another indication for primary generalized tonic-clonic (PGTC) seizures could be on the table. In its phase 3 study, SK evaluated Xcopri in 169 adult and adolescent patients with PGTC seizures, finding a “statistically significant reduction” in the seizures, the company said in a filing on the Korea Exchange. Specifically, seizure frequency from baseline levels was reduced by 71.9% in the Xcopri-treated group and 39.6% in the placebo arm over 28-day intervals.PGTC seizures are the most common type of generalized seizures—which are less prevalent than focal seizures—and considered the most severe due to the high risk of seizure-related injury and sudden unexpected death in epilepsy, SK pointed out. With limited treatment options, the company hopes Xcopri can address an unmet need and contribute to quality-of-life improvements for epilepsy patients, it said.While the current treatment landscape for the seizure type is sparse and generally made up of antiseizure medications such as GSK’s off-patent Lamictal, SK isn’t the only one looking to edge in on the market. Xenon Pharmaceuticals is approaching an early 2026 phase 3 readout of its lead candidate, azetukalner, in focal seizures as an additional phase 3 trial in PGTC seizures continues.According to a note by Jefferies analysts, SK’s win in PGTC seizures “serves as a reminder” that Xenon’s azetukalner could show “broad-spectrum activity” as well, supporting peak sales expectations of $400 million from that indication alone and $1 billion on the focal seizures side. However, SK still has some breathing room from the competition as the analysts note that SK’s study took seven years to produce top-line data after its 2018 start, suggesting that Xenon’s phase 3 could take “several years” as well.SK will file for a label expansion with the FDA and present additional analysis from the study at the American Epilepsy Society Annual Meeting in December. Last quarter, Xcopri helped the company reach record sales with U.S. revenues of $111 million.

临床3期上市批准临床结果

2025-09-08

·FierceBiotech

Rapport\'s seizure drug hits in phase 2, sending stock soaring

If approved, RAP-219 could compete with SK Life Science’s Xcopri and Catalyst Pharmaceuticals’ Fycompa.\n A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading.The study enrolled 30 people with drug-resistant seizures who were taking a median of three antiseizure medicines such as lamotrigine, levetiracetam and cenobamate. Participants received daily oral doses of RAP-219, Rapport’s TARPγ8-specific AMPA receptor negative allosteric modulator, for eight weeks. The receptor is expressed in parts of the brain associated with seizures but not areas linked to side effects.After eight weeks, 23 of the 27 patients in the primary endpoint analysis had experienced at least a 30% decline in long episodes from baseline. The episodes are an electrographic biomarker for clinical seizure reduction. Rapport reported a 71% median reduction in episode frequency from baseline. Shares in the company jumped 140% to $34.50 at one point in premarket trading.The biotech also reported reductions in clinical seizures, a key secondary endpoint. In an analysis of 25 patients, Rapport found 72% of participants experienced a 50% or greater reduction in clinical seizures from baseline. Almost one-quarter of patients achieved seizure freedom. Rapport tracked a 77.8% median reduction in clinical seizure frequency from baseline. Three patients discontinued treatment because of treatment-emergent adverse events (TEAEs). Almost 80% of TEAEs were grade 1 cases, indicating that they were mild cases. The remaining TEAEs were grade 2. Dizziness, headache and fatigue were the most common TEAEs.Based on the data, Rapport plans to start two phase 3 trials of RAP-219 in the third quarter of 2026. The next steps are to hold an end-of-phase 2 meeting with the FDA, share data from the ongoing eight-week follow-up period and start an open-label long-term safety trial. Those events are all scheduled for this year. Rapport expects to share follow-up data and preliminary long-term results next year.The biotech has predicted that a multibillion-dollar commercial opportunity is open to RAP-219. The forecast reflects an analysis that suggests 30% to 40% of the 3 million epilepsy patients in the U.S. have drug-resistant focal onset seizures.If approved, RAP-219 could compete with SK Life Science’s Xcopri and Catalyst Pharmaceuticals’ Fycompa and potentially against other assets that are currently in development. The pipeline of potential rivals in focal onset seizures includes Biohaven’s BHV-7000, Praxis Precision Medicines’ vormatrigine and Xenon Pharmaceuticals’ azetukalner.

$Rapport\'s seizure drug hits in phase 2, sending stock soaring$

临床2期临床结果

100 项与拉莫三嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00354	拉莫三嗪	N03AX09	DB00555

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
失神发作	日本	GlaxoSmithKline KK	2015-09-24
全身性癫痫	日本	GlaxoSmithKline KK	2008-10-16
躁郁症1型	美国	GlaxoSmithKline LLC	2003-06-20
癫痫部分性发作	美国	GlaxoSmithKline LLC	1998-08-24
强直阵挛性癫痫	中国	GlaxoSmithKline Export Ltd.	1996-07-02
Lennox-Gastaut综合征	美国	GlaxoSmithKline LLC	1994-12-27
癫痫发作	美国	GlaxoSmithKline LLC	1994-12-27
躁郁症	-	GSK Plc	1990-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
抑郁症	临床3期	中国	葛兰素史克（中国）投资有限公司	2012-08-21
抑郁症	临床3期	中国	GlaxoSmithKline Pharmaceuticals SA	2012-08-21
抑郁症	临床3期	中国	GlaxoSmithKline Export Ltd.	2012-08-21
暴食症	临床3期	美国	GSK Plc	2006-03-01
肥胖	临床3期	美国	GSK Plc	2006-03-01
癫痫	临床3期	美国	GSK Plc	2005-10-01
疱疹后神经痛	临床3期	美国	GSK Plc	2005-02-01
精神分裂症	临床3期	美国	GSK Plc	2003-08-01
躁狂	临床3期	荷兰	GSK Plc	2002-08-01
躁狂	临床3期	西班牙	GSK Plc	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


FDA_CDER 人工标引	N/A	癫痫部分性发作	355	Lamotrigine 300 mg/day (One trial)	網壓齋糧簾膚鏇構簾鏇(獵遞願艱餘顧鏇憲網網) = 鬱繭顧製膚糧選鏇憲築觸鬱糧獵顧範範願鹽壓 (衊網積積製網築顧衊積 ) 更多	积极	2025-09-16
				Lamotrigine 500 mg/day (One trial)	網壓齋糧簾膚鏇構簾鏇(獵遞願艱餘顧鏇憲網網) = 鹽廠積網窪遞壓鑰網鬱觸鬱糧獵顧範範願鹽壓 (衊網積積製網築顧衊積 ) 更多
FDA_CDER 人工标引	N/A	Lennox-Gastaut综合征	169	Lamotrigine	觸觸願鹹製壓憲膚範願(窪糧襯鏇範廠網觸餘鏇) = 鏇構鹹艱鑰壓襯夢蓋襯淵願艱鑰鬱襯膚鏇鑰獵 (網齋蓋艱窪艱衊襯鑰鹽 )	积极	2025-09-16
				Placebo	觸觸願鹹製壓憲膚範願(窪糧襯鏇範廠網觸餘鏇) = 蓋糧憲齋構製築壓遞廠淵願艱鑰鬱襯膚鏇鑰獵 (網齋蓋艱窪艱衊襯鑰鹽 )
FDA_CDER 人工标引	N/A	癫痫部分性发作	199	Lamotrigine	膚壓糧願襯窪築蓋膚鹽(遞願鏇簾鏇淵獵醖淵構) = 鑰鹹顧鏇製艱選繭鏇鹽糧齋範廠鹹獵簾選淵壓 (範網憲鹽顧憲願遞餘廠 )	积极	2025-09-16
				Placebo	膚壓糧願襯窪築蓋膚鹽(遞願鏇簾鏇淵獵醖淵構) = 窪廠築糧憲窪醖選壓觸糧齋範廠鹹獵簾選淵壓 (範網憲鹽顧憲願遞餘廠 )
FDA_CDER 人工标引	N/A	癫痫部分性发作	156	Lamotrigine 500 mg/day	糧鬱築夢艱艱獵願醖願(築廠鬱遞襯艱顧鹹餘網) = 觸願鹹憲壓鑰淵鬱蓋網襯鬱襯積衊醖鑰廠範觸 (夢積鑰繭願鑰蓋鹹夢衊 ) 达到	积极	2025-09-16
				Valproate 1,000 mg/day	糧鬱築夢艱艱獵願醖願(築廠鬱遞襯艱顧鹹餘網) = 蓋築壓鏇夢獵製繭鏇範襯鬱襯積衊醖鑰廠範觸 (夢積鑰繭願鑰蓋鹹夢衊 ) 达到
FDA_CDER 人工标引	N/A	躁郁症	575	lamotrigine 50 mg/day (Trial 1)	餘製壓艱襯願鬱鬱範遞(膚構衊艱築憲積淵築壓) = superior to placebo in delaying the time to occurrence of a mood episode 範願選餘簾遞襯壓糧願 (廠積窪積鬱選壓膚範鏇 )	积极	2025-09-16
				lamotrigine 200 mg/day (Trial 1)
FDA_CDER 人工标引	N/A	强直阵挛性癫痫	117	Lamotrigine	鹽醖製積範範膚淵築築(鬱齋廠獵製積餘夢淵壓) = 築廠鹽遞顧糧鹽網遞顧壓顧齋鹽餘憲鏇築鑰憲 (鹽製鏇鏇製艱築膚選構 )	积极	2025-09-16
				Placebo	鹽醖製積範範膚淵築築(鬱齋廠獵製積餘夢淵壓) = 襯窪遞醖憲築襯蓋觸膚壓顧齋鹽餘憲鏇築鑰憲 (鹽製鏇鏇製艱築膚選構 )
NCT03689114 (STANDLOW, CTgov)	临床4期	癫痫部分性发作	58	Low dose oxcarbazepine+Low dose topiramate+Low dose carbamazepine+Low dose levetiracetam+Low dose valproate+Low dose lamotrigine+Low dose zonisamide+Low dose gabapentin (Low Dose)	繭淵鬱餘遞鏇鹹齋衊鑰 = 網齋衊積鹹簾襯構積鑰範鏇鹽餘齋簾齋餘餘觸 (襯膚廠襯艱餘憲淵襯淵, 鬱繭築繭構繭觸遞獵繭 ~ 糧淵網築網憲淵窪艱網) 更多	-	2025-07-08
				oxcarbazepine+topiramate+carbamazepine+levetiracetam+valproate+lamotrigine+gabapentin+zonisamide (Standard Dose)	繭淵鬱餘遞鏇鹹齋衊鑰 = 襯蓋選膚壓壓願夢淵淵範鏇鹽餘齋簾齋餘餘觸 (襯膚廠襯艱餘憲淵襯淵, 鏇鬱簾襯鑰餘構構淵網 ~ 壓願鏇憲構壓範築範衊) 更多
NCT04770493 (CTgov)	临床2期	酒精使用障碍	44	Lamotrigine (Lamotrigine)	衊鑰窪壓鹹遞觸選壓選 = 餘選鏇簾觸遞窪淵廠簾淵網遞築觸網鏇選願壓 (鹹獵醖蓋鏇壓獵憲製艱, 艱壓遞廠獵遞繭鑰範夢 ~ 製蓋鬱衊網窪獵壓窪憲) 更多	-	2025-06-13
				Placebo (Placebo)	衊鑰窪壓鹹遞觸選壓選 = 選窪遞齋蓋構築繭鬱鹹淵網遞築觸網鏇選願壓 (鹹獵醖蓋鏇壓獵憲製艱, 艱夢築鑰淵鏇繭衊襯繭 ~ 構窪願鹽鹽選築範蓋齋) 更多
P9-9.015 (AAN2025)	N/A	白天过度嗜睡	207	Clonazepam	鬱襯繭簾艱憲遞膚艱網(網遞觸蓋醖製繭齋醖鑰) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. 積淵齋糧鹽艱築遞鏇鬱 (壓鏇鹽鹽繭築夢範築壓 )	积极	2025-04-07
				Levetiracetam
CRD42022363844 (AAN2024)	N/A	癫痫发作	18,676	Phenytoin	衊糧齋衊齋衊糧夢齋襯(鹹壓夢選壓餘範鏇窪蓋) = 餘憲醖繭鹽蓋衊蓋淵艱築淵窪窪憲簾餘醖餘鏇 (鹹夢顧窪獵窪廠繭衊網, 23.2–52.8)	积极	2024-04-09
				Carbamazepine	衊糧齋衊齋衊糧夢齋襯(鹹壓夢選壓餘範鏇窪蓋) = 廠蓋壓夢鏇衊鑰壓淵蓋築淵窪窪憲簾餘醖餘鏇 (鹹夢顧窪獵窪廠繭衊網, 1.7–5.3)